Health reform is expected to be a boon to biotech industry

03/23/2010 | American City Business Journals

Biotech firms and venture capitalists might be able to recover their investments in brand-name drugs with the passage of health care reform, which includes a measure that provides 12-year market exclusivity to original biotech treatments.

View Full Article in:

American City Business Journals